A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-Small Cell Lung Cancer

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.00195
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

Frontiers in Oncology
Cancer ResearchOncology
2019English

Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Immunotherapy
OncologyAllergyImmunology
2019English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2020English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

Safety and Tolerability of Extracranial Radiation Therapy and Immune Checkpoint Inhibitors Among Patients With Metastatic Non-Small Cell Lung Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy